27Oct 2023
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer

Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer

In a groundbreaking study, the OVHIPEC-1 trial revealed that adding hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery significantly enhanced survival for stage III epithelial ovarian cancer patients ineligible for primary surgery. The 10-year follow-up, involving 245 patients, demonstrated that the surgery-plus-HIPEC group had superior progression-free survival (14.3 months vs. 10.7 months) and overall survival (44.9 months vs. 33.3 months) compared to the surgery-only group. These findings underline the long-term efficacy of HIPEC in improving outcomes for this patient population, offering a significant stride in ovarian cancer treatment.

  • #oncology

Like

Save

Share